The Rhode Island-Israel Collaborative (RIIC) and RI Bio Sign Collaboration Agreement

ribiogood logo

March 26, 2019 – Carol C. Malysz, Executive Director of RI Bio and Avi Nevel, President of the Rhode Island-Israel Collaborative (RIIC) signed a collaboration agreement between both organizations on March 26, 2019.  As part of the agreement, both organizations will assist in connecting their members and network, plan future events together, relevant to RI Bio and Israeli companies, organizations and researchers via the Rhode Island-Israel Collaborative (RIIC).  Members of both organizations will also enjoy joint benefits.

(Pictured from left to right, Avi Nevel and Carol Malysz)

ABOUT the Rhode Island-Israel Collaborative (RIIC)

The Purpose of The Rhode Island-Israel Collaborative (RIIC) is the Promotion of Commerce, Academics and Science.

The collaborative is a not-for-profit organization that fosters and strengthens trade, business, academic exchange and research between Rhode Island and Israel to benefit the economy and community of each location. The Rhode Island-Israel Collaborative (RIIC) does so by building and strengthening the relationships between government organizations, businesses, entrepreneurs, investors, members of academia and the research community in Rhode Island and Israel.
Visit us at www.theriic.org

ABOUT RI Bio

RI Bio is Southeastern New England’s life sciences industry group. We are dedicated to galvanizing collaboration and growth among life sciences companies, hospitals, universities, sources of capital and governmental partners. We convene, advise and advocate. We work to secure resources to support the life sciences community and provide our members with exclusive access to regional/industry news, events, materials and supplies, workspaces, growth partners, and more. Visit us at www.ri-bio.org.

For more information, contact:

Avi Nevel at [email protected]

Carol Malysz at [email protected]

Latest News

DRIVEN/RI-INBRE Ignition Fund FOA – DEADLINE January 11, 2021

Funding is sparse for commercial-focused biomedical projects due to their inherent risks. The DRIVEN Accelerator Hub, an NIH/NIGMS-funded consortium serving biomedical entrepreneurs in Northeast IDeA states (https://www.drivenacceleratorhub.com/), is pleased to offer...

Slater Technology Fund-backed company to be acquired by Novartis

Slater Technology Fund-backed company to be acquired by Novartis

PROVIDENCE – The Cambridge, Mass.-based company Cadent Therapeutics has entered into an agreement to be acquired by Novartis in a deal worth up to $770 million, Slater Technology Fund announced Friday. The company was formed through a merger with the Slater Technology...

Biotech Industry News